Related Experiment Videos
Efficacy of mitomycin C against alveolar Echinococcus.
1Department of Biology, University of Winnipeg, Manitoba, Canada.
International Journal for Parasitology
|February 1, 1990
Summary
Mitomycin C demonstrated significant efficacy against Echinococcus multilocularis metacestodes in jirds. Treatment achieved 61-76% efficacy within one month across various dosages.
Area of Science:
- Parasitology
- Pharmacology
- Infectious Diseases
Background:
- Echinococcus multilocularis causes alveolar echinococcosis, a severe parasitic disease.
- The metacestode stage is the primary target for antiparasitic interventions.
- Limited effective treatments exist for established alveolar echinococcosis.
Purpose of the Study:
- To evaluate the efficacy of Mitomycin C against the metacestode stage of Echinococcus multilocularis.
- To determine the effective dosage range of Mitomycin C for treating E. multilocularis infection.
Main Methods:
- In vivo study using jirds (Meriones unguiculatus) infected with Echinococcus multilocularis metacestodes.
- Administration of varying total doses of Mitomycin C (0.04, 0.08, or 0.3 mg).
- Assessment of treatment efficacy at 1 month post-administration.
Main Results:
- Mitomycin C treatment resulted in 61-76% efficacy against E. multilocularis metacestodes.
- Efficacy was observed within a 1-month treatment period.
- The tested dosages showed comparable efficacy rates.
Conclusions:
- Mitomycin C exhibits significant antiparasitic activity against Echinococcus multilocularis metacestodes.
- The drug shows promise as a potential therapeutic agent for alveolar echinococcosis.
- Further research is warranted to explore Mitomycin C's clinical application in humans.